| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:56 UTC |
|---|
| HMDB ID | HMDB0015315 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Domperidone |
|---|
| Description | Domperidone is only found in individuals that have used or taken this drug. It is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem]Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting |
|---|
| Structure | ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2 InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30) |
|---|
| Synonyms | | Value | Source |
|---|
| 1-(3-(4-(5-Chloro-2-oxo-2,3-dihydrobenzo[D]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[D]imidazol-2(3H)-one | ChEBI | | 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone | ChEBI | | 5-Chloro-1-(1-(3-(2-oxo-2,3-dihydrobenzo[D]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[D]imidazol-2(3H)-one | ChEBI | | 5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one | ChEBI | | Domperidona | ChEBI | | Domperidonum | ChEBI | | Motilium | Kegg | | Domperidon hexal | HMDB | | Domperidon teva | HMDB | | Domperidon-teva | HMDB | | Domperidone monohydrochloride | HMDB | | Gastrocure | HMDB | | Novopharm brand OF domperidone maleate | HMDB | | PMS-Domperidone | HMDB | | Ratiopharm brand OF domperidone maleate | HMDB | | Apo domperidone | HMDB | | Domperidon | HMDB | | Domperidon al | HMDB | | Domperidon stada | HMDB | | Domperidona gamir | HMDB | | Domperidone maleate | HMDB | | Gry brand OF domperidone maleate | HMDB | | Nauzelin | HMDB | | Nu-pharm brand OF domperidone maleate | HMDB | | Rottapharm brand OF domperidone | HMDB | | Stadapharm brand OF domperidone maleate | HMDB | | Taxandria brand OF domperidone maleate | HMDB | | Ratio domperidone | HMDB | | Domidon | HMDB | | Domperidone maleate (1:1) | HMDB | | Hexal, domperidon | HMDB | | Monohydrochloride, domperidone | HMDB | | Novo domperidone | HMDB | | Nu pharm brand OF domperidone maleate | HMDB | | PMS Domperidone | HMDB | | Pharmascience brand OF domperidone maleate | HMDB | | Pierre fabre brand OF domperidone | HMDB | | Teva brand OF domperidone maleate | HMDB | | Ratio-domperidone | HMDB | | Aliud brand OF domperidone maleate | HMDB | | Apo-domperidone | HMDB | | Apotex brand OF domperidone maleate | HMDB | | Gamir, domperidona | HMDB | | Hexal brand OF domperidone maleate | HMDB | | Janssen brand OF domperidone | HMDB | | Maleate, domperidone | HMDB | | Novo-domperidone | HMDB | | Nu domperidone | HMDB | | Nu-domperidone | HMDB | | Péridys | HMDB | | Stada, domperidon | HMDB |
|
|---|
| Chemical Formula | C22H24ClN5O2 |
|---|
| Average Molecular Weight | 425.911 |
|---|
| Monoisotopic Molecular Weight | 425.161852744 |
|---|
| IUPAC Name | 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one |
|---|
| Traditional Name | motilium |
|---|
| CAS Registry Number | 57808-66-9 |
|---|
| SMILES | ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2 |
|---|
| InChI Identifier | InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30) |
|---|
| InChI Key | FGXWKSZFVQUSTL-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds). |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzimidazoles |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Benzimidazoles |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzimidazole
- Aryl chloride
- Aryl halide
- N-substituted imidazole
- Piperidine
- Benzenoid
- Azole
- Imidazole
- Heteroaromatic compound
- Tertiary aliphatic amine
- Tertiary amine
- Urea
- Azacycle
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Organic oxide
- Organopnictogen compound
- Amine
- Organic oxygen compound
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 242.5 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.092 g/L | Not Available | | LogP | 2.4 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.91 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.0465 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.71 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 43.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1473.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 189.7 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 179.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 172.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 169.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 394.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 384.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 151.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 830.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 432.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1110.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 288.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 303.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 492.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 141.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 11.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Domperidone,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)[NH]C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 3769.4 | Semi standard non polar | 33892256 | | Domperidone,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)[NH]C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 3386.1 | Standard non polar | 33892256 | | Domperidone,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)[NH]C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 4930.1 | Standard polar | 33892256 | | Domperidone,1TMS,isomer #2 | C[Si](C)(C)N1C(=O)N(C2CCN(CCCN3C(=O)[NH]C4=CC=CC=C43)CC2)C2=CC=C(Cl)C=C21 | 3756.8 | Semi standard non polar | 33892256 | | Domperidone,1TMS,isomer #2 | C[Si](C)(C)N1C(=O)N(C2CCN(CCCN3C(=O)[NH]C4=CC=CC=C43)CC2)C2=CC=C(Cl)C=C21 | 3416.5 | Standard non polar | 33892256 | | Domperidone,1TMS,isomer #2 | C[Si](C)(C)N1C(=O)N(C2CCN(CCCN3C(=O)[NH]C4=CC=CC=C43)CC2)C2=CC=C(Cl)C=C21 | 4971.0 | Standard polar | 33892256 | | Domperidone,2TMS,isomer #1 | C[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)N([Si](C)(C)C)C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 3792.6 | Semi standard non polar | 33892256 | | Domperidone,2TMS,isomer #1 | C[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)N([Si](C)(C)C)C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 3403.0 | Standard non polar | 33892256 | | Domperidone,2TMS,isomer #1 | C[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)N([Si](C)(C)C)C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 4536.6 | Standard polar | 33892256 | | Domperidone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)[NH]C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 3897.6 | Semi standard non polar | 33892256 | | Domperidone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)[NH]C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 3570.7 | Standard non polar | 33892256 | | Domperidone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)[NH]C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 4917.2 | Standard polar | 33892256 | | Domperidone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C(=O)N(C2CCN(CCCN3C(=O)[NH]C4=CC=CC=C43)CC2)C2=CC=C(Cl)C=C21 | 3894.1 | Semi standard non polar | 33892256 | | Domperidone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C(=O)N(C2CCN(CCCN3C(=O)[NH]C4=CC=CC=C43)CC2)C2=CC=C(Cl)C=C21 | 3600.9 | Standard non polar | 33892256 | | Domperidone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C(=O)N(C2CCN(CCCN3C(=O)[NH]C4=CC=CC=C43)CC2)C2=CC=C(Cl)C=C21 | 4963.7 | Standard polar | 33892256 | | Domperidone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)N([Si](C)(C)C(C)(C)C)C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 4074.6 | Semi standard non polar | 33892256 | | Domperidone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)N([Si](C)(C)C(C)(C)C)C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 3740.7 | Standard non polar | 33892256 | | Domperidone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)N(CCCN2CCC(N3C(=O)N([Si](C)(C)C(C)(C)C)C4=CC(Cl)=CC=C43)CC2)C2=CC=CC=C21 | 4543.0 | Standard polar | 33892256 |
|
|---|
| General References | - Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A: Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther. 1998 May-Jun;20(3):438-53. [PubMed:9663360 ]
|
|---|